GO:0070291 N-acylethanolamine metabolic process: Signaling Lipid Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070291 (N-acylethanolamine metabolic process) describes the biochemical reactions and pathways that synthesize and degrade N-acylethanolamines (NAEs), a family of signaling lipids that includes anandamide and palmitoylethanolamide.
• NAE metabolism is a two-sided system: N-acyl-phosphatidylethanolamine (NAPE) is formed from phosphatidylethanolamine and then hydrolyzed to release NAEs, while NAAA and FAAH hydrolyze NAEs to terminate signaling.
• The pathway is conserved from plants to mammals, and in plants NAE-mediated signaling regulates growth, development and stress responses.
• NAE levels rise during neurotoxic insults such as glutamate excitotoxicity, linking this metabolic process to neuroprotection and neurodegeneration.
• NAAA is a lysosomal cysteine amidase that is a validated drug target for pain and inflammation, and its inhibition elevates palmitoylethanolamide and anandamide.
• NAEs are being explored as therapeutics and biomarkers in pain, inflammation, cancer and metabolic disease, making this pathway a rich source of CRISPR-editable targets.
Description
N-acylethanolamine metabolic process (GO:0070291) is the biological process that governs the chemical reactions and pathways involving N-acylethanolamines, a class of ethanolamine-derived lipids in which an acyl group is attached to the nitrogen. These lipids, often called NAEs, include well-known signaling molecules such as anandamide (N-arachidonoylethanolamine) and palmitoylethanolamide (PEA), and they act as endogenous mediators in the nervous system, immune system and peripheral tissues. The term is defined in QuickGO as the chemical reactions and pathways involving N-acylethanolamines, and it encompasses both biosynthetic and degradative arms of the pathway. Researchers study GO:0070291 because it sits at the intersection of lipid biochemistry, endocannabinoid signaling and inflammation resolution. The pathway is initiated by the formation of N-acyl-phosphatidylethanolamine (NAPE) from phosphatidylethanolamine, followed by hydrolysis to release NAEs, and it is terminated by amidases such as NAAA and FAAH. Because NAE levels are tightly controlled, perturbations in this process have been linked to pain, neuroinflammation, neurodegeneration and cancer biology. From a methodological standpoint, GO:0070291 is a tractable process for CRISPR-based interrogation: key enzymes such as NAAA, FAAH, NAPE-PLD and related acyltransferases can be knocked out, point-mutated or overexpressed to dissect their contributions to NAE flux and downstream phenotypes. This article summarizes the authoritative QuickGO definition, the mechanistic stages of the pathway, the genes involved, disease links and the experimental models used to study it.
N-acylethanolamine metabolic process At A Glance
| GO ID | GO:0070291 |
|---|---|
| GO term | N-acylethanolamine metabolic process |
| Ontology | biological_process |
| Synonym | N-acylethanolamine metabolism; NAE metabolic process; NAE metabolism |
| Definition | The chemical reactions and pathways involving N-acylethanolamines, an ethanolamine substituted at nitrogen by an acyl group |
| Major function | Synthesis and degradation of NAE signaling lipids such as anandamide and palmitoylethanolamide |
| Key enzymes | NAAA, FAAH, NAPE-PLD and NAPE-forming acyltransferases |
| Subcellular context | Membrane-associated biosynthesis and lysosomal/endosomal hydrolysis |
| Organism scope | Conserved in mammals and plants |
What Is GO:0070291?
In plain terms, GO:0070291 describes the set of biochemical reactions that make, modify and break down N-acylethanolamines, which are ethanolamine molecules carrying an acyl group on their nitrogen. The process includes the formation of N-acyl-phosphatidylethanolamine intermediates, the release of free NAEs, and their subsequent hydrolysis by amidases such as NAAA and FAAH. It is a biological_process term, meaning it describes a coordinated series of molecular events rather than a single molecular function or cellular location.
Why Is N-acylethanolamine metabolic process Important in Cell Biology?
GO:0070291 is important because N-acylethanolamines are lipid mediators that control pain, inflammation, neuroprotection and metabolic homeostasis, and their levels are dictated by the balance of biosynthetic and degradative reactions in this pathway. Dysregulation of NAE metabolism has been implicated in neurotoxicity and neurodegeneration, and the principal NAE-degrading enzyme NAAA is a validated target for analgesic and anti-inflammatory drug development. Understanding this process therefore informs both fundamental lipid signaling biology and translational efforts in pain, inflammation and cancer.
• NAEs such as anandamide and palmitoylethanolamide are endogenous signaling lipids with analgesic and anti-inflammatory activity.
• NAAA is a lysosomal cysteine amidase that hydrolyzes NAEs and is a druggable target for pain and inflammation.
• FAAH is a major endocannabinoid hydrolase that terminates anandamide signaling, linking this process to endocannabinoid tone.
• NAE formation increases during glutamate-induced neurotoxicity, suggesting a role in neuroprotective responses.
• The pathway is conserved in plants, where NAE-mediated signaling regulates development and stress responses.
• NAE metabolism intersects with lipid remodeling and membrane biology through NAPE intermediates.
• Pharmacological inhibition of NAAA elevates PEA and anandamide, supporting therapeutic exploration.
• NAE pathway genes are candidate biomarkers and drug targets in inflammatory and metabolic disease.
• CRISPR editing of NAAA, FAAH and NAPE-PLD enables causal testing of NAE flux in disease models.
• The pathway provides a bridge between endocannabinoid biology and broader lipid mediator research.
What Happens During N-acylethanolamine metabolic process?
Formation of N-acyl-phosphatidylethanolamine (NAPE)
In simple terms: The pathway starts by attaching a fatty acid to a membrane lipid called phosphatidylethanolamine.
The first committed step in NAE biosynthesis is the transfer of an acyl group from a donor phospholipid to phosphatidylethanolamine, generating N-acyl-phosphatidylethanolamine (NAPE). This reaction is catalyzed by NAPE-forming acyltransferases and establishes the membrane-bound precursor pool from which NAEs are later released. NAPE is a key intermediate because its abundance sets the ceiling for subsequent NAE production.
Release of free N-acylethanolamines
In simple terms: Enzymes then cut NAPE to liberate the active signaling lipids.
NAPE is hydrolyzed by phospholipase D-type enzymes, notably NAPE-PLD, to release free N-acylethanolamines such as anandamide and palmitoylethanolamide. This step converts an inactive membrane phospholipid into bioactive lipid mediators that can engage receptors and other targets. The reaction is a central control point because it determines the size of the free NAE pool.
Hydrolysis of NAEs by NAAA
In simple terms: A lysosomal enzyme called NAAA breaks down NAEs to switch off their signals.
N-acylethanolamine acid amidase (NAAA) is a lysosomal cysteine amidase that hydrolyzes NAEs, including palmitoylethanolamide and anandamide, into ethanolamine and the corresponding fatty acid. NAAA is optimally active at acidic pH, consistent with its lysosomal localization, and its inhibition elevates NAE levels in cells and tissues. Because of its role in terminating NAE signaling, NAAA is a major therapeutic target in this pathway.
Hydrolysis of NAEs by FAAH
In simple terms: Another enzyme, FAAH, also degrades NAEs and is especially important for anandamide.
Fatty acid amide hydrolase (FAAH) is a well-characterized endocannabinoid hydrolase that hydrolyzes anandamide and other NAEs, thereby terminating their signaling. FAAH and NAAA together provide redundant and complementary routes for NAE catabolism, and their relative contributions vary by tissue and substrate. This dual-enzyme architecture makes the pathway robust and creates opportunities for selective pharmacological or genetic intervention.
NAE signaling and downstream effects
In simple terms: Once released, NAEs act on receptors and other targets to produce biological effects.
Free NAEs such as anandamide and palmitoylethanolamide act as signaling lipids that modulate pain, inflammation and neuroprotection through receptor-dependent and receptor-independent mechanisms. Their levels rise during neurotoxic challenges such as glutamate-induced excitotoxicity, suggesting that NAE production is part of a stress-responsive lipid signaling program. The balance between NAE synthesis and degradation therefore determines the intensity and duration of these biological effects.
Key Genes Involved in GO:0070291 N-acylethanolamine metabolic process
The following genes and proteins are the principal enzymes and regulators that carry out or control N-acylethanolamine metabolic process (GO:0070291).
| Gene | Major Role | Research Relevance |
|---|---|---|
| NAAA | Lysosomal cysteine amidase that hydrolyzes NAEs | Validated drug target for pain and inflammation; KO elevates NAE levels |
| FAAH | Endocannabinoid hydrolase that degrades anandamide and other NAEs | Central to endocannabinoid tone; KO increases anandamide |
| NAPE-PLD | Phospholipase D that releases NAEs from NAPE | Controls free NAE pool size; KO reduces anandamide |
| NAPEPLD | Alternative symbol for NAPE-PLD | Same enzyme; relevant for nomenclature and database searches |
| PLA2G4E | Phospholipase A2 family member implicated in NAE precursor metabolism | Candidate for NAPE hydrolysis; requires experimental validation |
| ABHD4 | Alpha/beta hydrolase domain protein involved in NAE precursor processing | Potential alternative NAE biosynthetic route |
| GDE1 | Glycerophosphodiesterase that can hydrolyze NAPE | Alternative NAE-producing enzyme; context-dependent |
| PTGS2 | Cyclooxygenase-2 that can oxygenate NAEs | Links NAE metabolism to prostaglandin-like mediators |
| LOX | Lipoxygenase enzymes that oxidize NAEs | Generates oxidized NAE metabolites with distinct bioactivity |
| CYP450 | Cytochrome P450 enzymes that oxidize NAEs | Produces epoxy and hydroxy NAE derivatives |
| TRPV1 | Ion channel activated by anandamide | Mediates NAE-dependent pain signaling |
| PPAR-alpha | Nuclear receptor activated by PEA and other NAEs | Mediates anti-inflammatory and analgesic effects |
| GPR55 | Orphan GPCR responsive to NAEs | Candidate NAE receptor; ongoing research |
| CB1 | Cannabinoid receptor 1 activated by anandamide | Classic endocannabinoid target |
| CB2 | Cannabinoid receptor 2 activated by endocannabinoids | Immune and inflammatory signaling |
| NAT | N-acyltransferase activity that forms NAPE | Upstream biosynthetic step; enzyme identity context-dependent |
| PLD | Phospholipase D activity releasing NAEs | Biosynthetic release step; multiple isoforms |
| FAAH2 | FAAH-like amidase | Potential redundant NAE hydrolase; species-specific |
How Is N-acylethanolamine metabolic process Regulated?
N-acylethanolamine metabolic process is regulated at multiple levels. Enzyme abundance and activity of NAAA and FAAH determine the rate of NAE hydrolysis, and NAAA is active at acidic pH, linking its function to lysosomal status. NAPE-PLD controls the release of NAEs from NAPE, so changes in its expression or activity directly alter free NAE levels. In addition, NAE production increases during glutamate-induced neurotoxicity, indicating that the pathway is responsive to excitotoxic stress. Pharmacological inhibition of NAAA elevates PEA and anandamide, demonstrating that enzyme activity is a key regulatory node.
N-acylethanolamine metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NAAA | Inflammatory and neuropathic pain | NAAA knockout or point-mutation cell lines with NAE measurement |
| FAAH | Endocannabinoid-related pain and anxiety | FAAH knockout cells and anandamide quantification |
| NAPE-PLD | Reduced NAE biosynthesis | NAPE-PLD knockout or overexpression models |
| PTGS2 | NAE oxidation and inflammatory mediators | PTGS2 knockout with oxidized NAE profiling |
| TRPV1 | NAE-dependent pain signaling | TRPV1 knock-in or point-mutation for agonist sensitivity |
Pain and Inflammation
NAEs such as palmitoylethanolamide and anandamide exert analgesic and anti-inflammatory effects, and NAAA inhibition elevates these lipids to reduce pain and inflammation in preclinical models. This makes GO:0070291 a direct therapeutic axis for inflammatory and neuropathic pain.
Neurodegeneration and Neurotoxicity
NAE formation increases during glutamate-induced neurotoxicity, and dysregulated NAE signaling has been discussed in the context of neurodegenerative processes. The pathway is therefore studied for its potential neuroprotective roles.
Cancer and Metabolic Disease
NAEs and their oxidized metabolites have been implicated in cancer biology and metabolic regulation, and the enzymes of this pathway are being explored as biomarkers and drug targets. The therapeutic opportunities of NAE signaling are an active area of research.
From N-acylethanolamine metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NAAA increase NAE levels? | NAAA knockout cell line with LC-MS lipidomics |
| Does a catalytic cysteine mutation abolish NAAA activity? | NAAA point-mutation knock-in |
| Does NAPE-PLD overexpression raise anandamide? | NAPE-PLD overexpression cell model |
| Can a tagged NAAA be used for localization studies? | Tagged knock-in of NAAA |
| Does FAAH deletion alter anandamide signaling? | FAAH knockout cells and receptor assays |
| Which genes control NAE flux under stress? | CRISPR library screening with NAE readouts |
How to Study the N-acylethanolamine metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS lipidomics | Levels of anandamide, PEA and other NAEs | Quantifying pathway output |
| Fluorogenic amidase assay | NAAA or FAAH catalytic activity | Enzyme kinetics and inhibitor testing |
| CRISPR knockout | Loss-of-function effect on NAE levels | Causal gene testing |
| CRISPR point mutation | Effect of specific catalytic residues | Mechanistic enzymology |
| Overexpression | Gain-of-function effect on NAE flux | Pathway amplification studies |
| Tagged knock-in | Protein localization and interactions | Imaging and proteomics |
| CRISPR library screening | Genome-wide modifiers of NAE metabolism | Discovery of new pathway genes |
| Transcriptomics | Expression changes in NAE pathway genes | Context-dependent regulation |
Lipidomics and Mass Spectrometry
Targeted LC-MS/MS is the primary method to quantify NAEs such as anandamide and palmitoylethanolamide, and it is used to measure pathway output after genetic or pharmacological perturbation.
Enzyme Activity Assays
NAAA and FAAH amidase activities are measured using fluorogenic or radiolabeled substrates, allowing direct assessment of catalytic function and inhibitor potency.
CRISPR-Based Genetic Perturbation
Knockout, point-mutation and overexpression models of NAAA, FAAH and NAPE-PLD are used to establish causal roles of individual enzymes in NAE metabolism.
Expression and Localization Studies
Antibody-based detection, tagged knock-in and imaging approaches reveal where NAE enzymes localize and how their expression changes across conditions.
How CRISPR Can Be Used to Study GO:0070291 N-acylethanolamine metabolic process
Knockout
CRISPR knockout of NAAA, FAAH or NAPE-PLD is used to remove enzyme activity and measure consequent changes in NAE levels and downstream phenotypes.
Point Mutation
Point mutation of catalytic residues, such as the NAAA cysteine nucleophile, allows precise testing of enzyme mechanism without deleting the entire protein.
Knock-in
Knock-in of tags or reporter sequences at NAE pathway loci enables localization, interaction and real-time activity studies.
Overexpression
Overexpression of NAPE-PLD or other biosynthetic enzymes increases NAE production and is used to test sufficiency in signaling and disease models.
How EDITGENE Supports N-acylethanolamine metabolic process Research
Researchers studying N-acylethanolamine metabolic process-related genes often need to determine whether a candidate gene is causally involved in NAE synthesis or degradation, and CRISPR-based models provide the most direct way to test that causality. By combining knockout, point-mutation, knock-in and overexpression strategies with lipidomics and functional assays, it is possible to move from correlation to mechanism in this pathway.
Contact EDITGENE today to design your custom CRISPR model for N-acylethanolamine metabolic process research.
Frequently Asked Questions About N-acylethanolamine metabolic process
What is N-acylethanolamine metabolic process (GO:0070291)?
It is the biological process comprising the chemical reactions and pathways that synthesize and degrade N-acylethanolamines, a class of signaling lipids including anandamide and palmitoylethanolamide.
What genes are involved in N-acylethanolamine metabolic process?
Key genes include NAAA, FAAH, NAPE-PLD and related acyltransferases and phospholipases that form and hydrolyze NAE intermediates.
What is the role of NAAA in N-acylethanolamine metabolism?
NAAA is a lysosomal cysteine amidase that hydrolyzes NAEs such as palmitoylethanolamide and anandamide, terminating their signaling.
How is anandamide degraded?
Anandamide is degraded primarily by FAAH and, in acidic compartments, by NAAA, which hydrolyze it to ethanolamine and arachidonic acid.
Why is N-acylethanolamine metabolism important for pain?
NAEs such as palmitoylethanolamide have analgesic and anti-inflammatory effects, and inhibiting their degradation elevates these lipids to reduce pain.
Is N-acylethanolamine metabolism conserved in plants?
Yes, NAE-mediated regulatory pathways exist in plants and control growth, development and stress responses.
What diseases are linked to N-acylethanolamine metabolic process?
The pathway has been linked to pain, inflammation, neurotoxicity and cancer biology through the actions of NAEs and their metabolites.
How can CRISPR be used to study N-acylethanolamine metabolism?
CRISPR knockout, point mutation, knock-in and overexpression of NAAA, FAAH or NAPE-PLD allow causal testing of enzyme function in NAE flux.
What methods measure N-acylethanolamine levels?
Targeted LC-MS/MS lipidomics is the standard method for quantifying anandamide, palmitoylethanolamide and other NAEs.
Does N-acylethanolamine metabolism change during neurotoxicity?
Yes, NAPE and NAE formation increases during glutamate-induced neurotoxicity, suggesting a stress-responsive role.
Conclusion
GO:0070291 (N-acylethanolamine metabolic process) defines the synthesis and degradation of NAE signaling lipids, a pathway with central roles in pain, inflammation, neuroprotection and metabolic regulation. Its key enzymes, including NAAA, FAAH and NAPE-PLD, are tractable targets for CRISPR-based interrogation and drug discovery. By combining precise genome editing with lipidomics and functional assays, researchers can establish causal links between NAE pathway genes and disease phenotypes, accelerating translational progress in this field.
References
- 1. Piomelli D et al.. 2020. N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition.. J Med Chem 63(14):7475-7490 PMID: 32191459
- 2. Ueda N et al.. 2010. N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA).. Prog Lipid Res 49(4):299-315 PMID: 20152858
- 3. Tsuboi K et al.. 2007. The N-acylethanolamine-hydrolyzing acid amidase (NAAA).. Chem Biodivers 4(8):1914-25 PMID: 17712833
- 4. Kilaru A et al.. 2007. The N-acylethanolamine-mediated regulatory pathway in plants.. Chem Biodivers 4(8):1933-55 PMID: 17712835
- 5. Ueda N. 2002. Endocannabinoid hydrolases.. Prostaglandins Other Lipid Mediat 68-69:521-34 PMID: 12432941
- 6. Rankin L et al.. 2020. The Basal Pharmacology of Palmitoylethanolamide.. Int J Mol Sci 21(21) PMID: 33114698
- 7. Mock ED et al.. 2023. Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.. Prog Lipid Res 89:101194 PMID: 36150527
- 8. Hansen HS et al.. 1999. Formation of N-acyl-phosphatidylethanolamine and N-acylethanolamine (including anandamide) during glutamate-induced neurotoxicity.. Lipids 34 Suppl:S327-30 PMID: 10419193
